Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
IRI developed a proprietary technology to extract polyclonal and monoclonal immunoglobulin antibodies from animal sources, targeting virus and bacteria-related health concerns. The company focused on commercializing these as nutraceuticals. There is no public record of clinical trial results or regulatory approvals for pharmaceutical indications
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on IRI Separation Technologies Inc..